United States Congress Passes Bill that Represents a Major

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
United States Congress Passes Bill that Represents a Major Opportunity for Regenerative Therapies
  • 21st Century Cures Act is expected by industry analysts to speed up drug development by accelerating the regulatory approval process
  • Pluristem’s program for CLI was already selected to rapid pathways in both Europe and Japan, where legislation similar to the 21 st Century Cures Act has already been passed

HAIFA, Israel, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (NasdaqCM:PSTI) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, welcomes and applauds the U.S. Congress’ passage of the 21 st Century Cures Act . Pluristem believes its PLX-PAD and PLX-R18 cell therapies will meet the criteria outlined by the Act as advanced regenerative therapies that can treat a wide range of disease. The 21 st Century Cures Act is expected by industry analysts to speed up drug development by accelerating the regulatory approval process, among other means.

“The 21 st Century Cures Act is an extremely significant healthcare legislation that may have a direct and beneficial impact on Pluristem’s clinical development programs and progress towards approval for our cell therapies,” stated Pluristem CEO Zami Aberman. “Pluristem has a robust portfolio of cell therapies that are designed to treat severe diseases where there is a high unmet medical need. The 21 st Century Cures Act should allow for early patient access to cell therapies, while also creating medical and economic benefits for the U.S. healthcare system. The passage of this legislation in the world’s largest healthcare market reinforces Pluristem’s strategy of pursuing accelerated pathways to market around the globe.”

Pluristem’s clinical program for CLI is already being developed via both Europe’s Adaptive Pathways project and the Japanese PMDA under the new legislation for conditional marketing authorization for regenerative therapies.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cell products release a range of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss our belief that our PLX-PAD and PLX-R18 cell therapies will meet the criteria outlined by the 21st Century Cures Act as advanced regenerative therapies that can treat a wide range of disease, when we discuss the expectation that the Act will speed up drug development by streamlining the regulatory approval process, when we discuss the Act’s potential to have a direct and beneficial impact on our clinical development and approval pathways for our cell therapy candidates, and when we discuss our clinical plans regarding the treatment of CLI and improving recovery after surgery for hip fracture, including the plans for FDA protocol submission and possible use of the new U.S. regulatory pathway. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact: Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 17

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 0

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 0

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 39

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 51

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

GrandCare Health Services Enhances Revenue with Smart Solutions

Updated Category News Views 120

GrandCare Health Services Takes a New Approach to Revenue Management In a strategic move to enhance its financial efficiency, GrandCare Health Services has recently partnered with Homecare Homebase (HCHB), a leading provider of cloud-based technological solutions designed for home health agencies. This collaboration specifically focuses on optimizing revenue cycle...

Continue Reading
Westland Insurance Expands its Ontario Footprint with Acquisition

Updated Category News Views 216

Westland Insurance Expands its Ontario Presence Westland Insurance, a prominent name in Canada’s insurance market, has made strides in enhancing its reach with the acquisition of Paul Ayotte Insurance Brokers Ltd. This strategic move aims to solidify Westland’s footprint in Ontario, allowing for improved service delivery to local clients. This acquisition not only...

Continue Reading
First Industrial Realty Trust Set for Q3 Results Conference Call

Updated Category News Views 50

First Industrial Realty Trust, Inc. (NYSE: FR) faced a pivotal moment back in late 2024, gearing up to unveil its third-quarter numbers. The desks were buzzing as traders anticipated this call—a regular event but always loaded with potential surprises. Q3 Results Anticipation: Supply Chain Stakes or Investor Optimism? On that Thursday morning, scheduled for 10:00 a.m....

Continue Reading
Fannie Mae Panel Predicts Slowdown in Future Home Prices

Updated Category News Views 217

Fannie Mae's Expert Insights on Home Price Trends A recent survey conducted by Fannie Mae proves insightful for those watching the housing market, as it sheds light on anticipated changes in home prices in the coming years. The report indicates that after an increase of 5.3% in 2024, experts expect a more moderate growth of approximately 2.4% for 2025 and 2.1% for 2026....

Continue Reading
PenKid Biomarker Revolutionizes Kidney Therapy Decisions

Updated Category News Views 31

The Emergence of PenKid in Critical Care You ever get the feeling that the old ways just aren’t cutting it anymore? That’s where this penKid news rolls in like a breath of fresh air. In the world of ICU management, especially with kidney replacement therapy (KRT), this little biomarker is flipping the script on traditional biomarkers. Imagine 1,436 critically ill...

Continue Reading